- 英文名称
- Prasugrel Hydrochloride
- 分子式
- C20H21ClFNO3S
- 分子量
- 409.9
- 中文别名
- 5-(2-环丙基-1-(2-氟苯基)-2-氧代乙基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基 乙酸酯盐酸盐; 普拉格雷盐酸盐; 2-[2-(乙酰氧基)-6,7-二氢噻吩并[3,2-C]吡啶-5(4H)-基]-1-环丙基-2-(2-氟苯基)乙酮盐酸盐; 拉格雷盐酸盐; 普拉格雷2; 格雷; 5-(2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride; [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate,hydrochloride; 5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride (1:1); Prasugrel hydrochloride; Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (1:1); Prasugren hydrochloride; Prasugrelhydrochloride; Efient; Prasugrel (hydrochloride); 2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone hydrochloride
- 用途
- 生命科学领域原料药;噻吩并吡啶类抗血小板药,是前体药物,经肝脏细胞色素P450代谢为活性分子,与血小板P2Y12受体结合发挥抗血小板聚集活性;60毫克剂量较氯吡格雷标准剂量抗凝血效果更好,降低心脏病发作、中风、心脏病死亡综合风险20%,见效快、疗效好、耐药性及生物利用度良好、毒性较低;血小板聚集抑制剂,用于急性冠脉综合征患者阻止血栓形成;单次或多次给药能显著抑制动静脉分流和电诱导的动脉血栓形成,阻止外周血管病变进展;抗血小板凝聚